Claim2085a3ff6af08933229cc05d8da1b19c788e1d24b994d7389c6c7410afa1ab5d·My Arguments

Claim

The most consistently documented long-term harm is loss of lean/muscle mass — up to roughly 40% of total weight lost can be fat-free mass — raising sarcopenia risk especially in older adults; however this is measurable and partly mitigable with resistance exercise and adequate protein rather than a contraindication.

Evidence (1)

SEMALEAN: impact of semaglutide on fat mass, lean mass and muscle function

A substantial fraction of semaglutide-induced weight loss is lean mass; magnitude is modifiable by physical activity and diet, motivating monitoring rather than avoidance.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12673431/

Dialectical view

Public arguments concluding to this claim, and structural counter-arguments that contest it.

Arguments for (1)

The most consistently documented long-term harm is loss of lean/muscle mass — up to roughly 40% of total weight lost can be fat-free mass — raising sarcopenia risk especially in older adults; however tested-undermined

Arguments against (0)

No structural counter-arguments are on file.

Browse all counter-arguments to this claim

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/2085a3ff6af08933229cc05d8da1b19c788e1d24b994d7389c6c7410afa1ab5d"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

View full deliberation Join & respond